Bulletin N 146 - February 2025
Procalcitonin and sepsis in critically ill patients
Sepsis is defined by the Sepsis-3 consensus as life-threatening organ dysfunction caused by a dysregulated host response to infection. Each hour of delay in diagnosis, attributable to failure to recognize it during patient admission, is associated with a 7% reduction in survival.
The need for early diagnosis has led to the search for a specific biomarker, which also allows risk stratification and prognosis and whose variation allows monitoring of subsequent evaluation. Procalcitonin (PCT) has revolutionized the management of sepsis, allowing a more accurate diagnosis and more efficient antibiotic management. This approach, combined with clinical strategies and the role of the laboratory, has significantly improved patient care.
The determination of PCT helps predicting bacterial infection, distinguishing it from viral infections and other inflammatory processes, and to differentiate between localized and systemic bacterial infection. It should not be used in isolation, but in combination with clinical evaluation and other microbiological data to make therapeutic decisions.